Cross-posted from Written Description, where it originally appeared on March 30, 2020.
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob Sherkow
One of the dizzying stream of innovation and health law stories to emerge last week is Oracle’s partnership with the White House to study unproven pharmaceuticals for treating COVID-19. We decided to unpack this story for ourselves and then to collectively share our thoughts in a short explainer.
Click here to read the full post at Written Description.
